Physician profile
Mukul V Patharkar
NPI 1922157338
$2,293.73
in general payments reported to CMS, 2019-2025
15 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $307 · 2021: $437 · 2022: $200 · 2023: $205 · 2024: $403 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $52.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.57 |
| Education | $52.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $381.30 | 2019-2025 | Biktarvy |
| Insmed, INC. | $263.27 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $244.03 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $238.60 | 2019-2020 | |
| Melinta Therapeutics, LLC | $231.94 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Cumberland Pharmaceuticals, INC. | $228.89 | 2022-2025 | Vibativ |
| Viiv Healthcare Company | $228.30 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Shionogi INC | $139.68 | 2021-2022 | |
| Janssen Biotech, INC. | $87.32 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $79.38 | 2021 | |
| Abbvie INC. | $75.34 | 2021-2025 | |
| Tetraphase Pharmaceuticals, INC. | $34.98 | 2019 | |
| Theratechnologies INC. | $21.52 | 2024 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $21.20 | 2024 | Nuzyra |
| Pfizer INC. | $17.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukul Patharkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.